Eli Lilly Retatrutide Achieves 22.6% Weight Loss in Phase 3 Trials

Eli Lilly announced positive results from two additional Phase 3 clinical trials for retatrutide, a next-generation obesity treatment administered once weekly, on the 23rd (US local time) according to CNBC. The trials demonstrated significant weight loss in patients with obesity-related conditions. The company adjusted its regulatory submission timeline from this year to Q1 next year to fully collect and verify manufacturing and quality control data required by authorities.

Eli Lilly Reports Weight Loss Results in Diabetic Patients

In the clinical trial targeting diabetic patients, those who received the drug experienced up to 20.8% weight loss at the 80-week mark, according to CNBC. Key blood sugar levels also showed meaningful improvement. Diabetic patient populations are typically known for facing significant challenges in achieving weight loss.

Eli Lilly Records Weight Reduction in Severe Obesity Patients

Adults with severe obesity and cardiovascular disease showed an average maximum weight reduction of 22.6% over 80 weeks in the clinical trial. Major cardiovascular risk factors in these patients also decreased significantly.

Retatrutide Shows GLP-1 Class Side Effects

Side effects observed during treatment included diarrhea, nausea, and constipation, consistent with the typical profile of existing GLP-1 class medications. With these results, retatrutide has now secured a total of 5 successful Phase 3 clinical datasets.

Eli Lilly Stock Closes Higher on Trial Results

Eli Lilly stock closed at $1,185.87, up $22.86 (1.97%) from the previous day.

FAQ

What weight loss did Eli Lilly's retatrutide achieve in Phase 3 trials?

Retatrutide achieved up to 20.8% weight loss in diabetic patients and up to 22.6% weight loss in adults with severe obesity and cardiovascular disease at 80 weeks in Phase 3 clinical trials announced on the 23rd (US local time).

When will Eli Lilly submit retatrutide for regulatory approval?

Eli Lilly adjusted its regulatory submission timeline to Q1 next year to fully collect and verify manufacturing and quality control data required by authorities, delaying from the original plan to submit this year.

What side effects does retatrutide cause?

Retatrutide's side effects include diarrhea, nausea, and constipation, consistent with the typical side effect profile of existing GLP-1 class medications.